Back to Sectors

CELC

Celcuity Inc.
3 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 90% | 3/26/2026 | guidance raiseBULLISH | 70% | 3/26/2026 | capital raiseBEARISH | 60% | 3/26/2026 | debt restructureBEARISH | 50% | 3/26/2026 | margin compressionBEARISH | 70% | 5/14/2026 | margin compressionBULLISH | 60% | 5/14/2026 | capital raiseBULLISH | 90% | 5/14/2026 | regulatory actionBEARISH | 70% | 5/14/2026 | margin compressionBULLISH | 60% | 5/14/2026 | capital raiseBULLISH | 90% | 5/14/2026 | regulatory actionMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 14

Operating losses increased 40% year-over-year due to aggressive commercial spending.

margin compression
70%
bullishMay 14

Secured contingent debt facilities totaling up to $220 million linked to FDA approval and revenue.

capital raise
60%
bullishMay 14

FDA granted Priority Review for gedatolisib with a PDUFA date of July 17, 2026.

regulatory action
90%
bearishMay 14

Operating losses increased 40% year-over-year due to aggressive commercial spending.

margin compression
70%
bullishMay 14

Secured contingent debt facilities totaling up to $220 million linked to FDA approval and revenue.

capital raise
60%
bullishMay 14

FDA granted Priority Review for gedatolisib with a PDUFA date of July 17, 2026.

regulatory action
90%
bullishMar 26

FDA Priority Review granted with a firm PDUFA date of July 17, 2026.

guidance raise
90%
bullishMar 26

Successfully raised significant capital in 2025 to ensure runway through 2027.

capital raise
70%
bearishMar 26

High leverage with over $338M in debt increasing financial risk profile.

debt restructure
60%
bearishMar 26

Net losses increased to $177M in 2025 due to scaling commercial infrastructure.

margin compression
50%

Filing History

10-QMay 14, 2026

The Q1 2026 filing paints a picture of a company at a critical inflection point. Celcuity has successfully navigated the clinical validation phase, with VIKTORIA-1 data providing a strong foundation for regulatory approval. The strategic shift in spending toward commercial readiness indicates that management is betting heavily on a successful July 17 outcome. The introduction of a subcutaneous formulation patent further suggests a long-term strategy to expand the drug's competitive moat and improve patient adherence. However, the synthesis of the financial data reveals a high-stakes gamble. The company's massive accumulated deficit of $501.7 million and the acceleration of operating losses highlight the inherent risks of the biotech model. Investors are now weighing the high probability of clinical success against the reality of a fragile balance sheet and a looming debt wall. The overall impact of the filing is a shift in focus from clinical milestones to commercial execution and liquidity management.

10-KMar 26, 2026

The 10-K reveals a company at a critical inflection point, balancing a fortress-like balance sheet against the inherent volatility of biotech drug approval. The successful completion of the VIKTORIA-1 trial and the subsequent FDA acceptance of the NDA signal that the clinical hurdles are largely behind the company, shifting the focus to regulatory and commercial execution. The primary tension for investors lies in the trade-off between the potential for a $2.5 billion peak revenue stream and the risk of a regulatory setback that would trigger a liquidity crisis given the current debt obligations. Ultimately, the filing confirms that Celcuity has the financial resources to survive the immediate term, but its long-term viability is inextricably linked to the July 17 PDUFA date. The transition to a commercial entity will require a flawless execution of its sales and distribution strategy, moving beyond the research-heavy focus of the last decade to establish a sustainable revenue base in a highly competitive oncology landscape.